Biogen Inc. (NASDAQ:BIIB) changes shares on Friday trading session, with a change of -1.51% or -$3.97 shares. The trading starts at $262.76 and closed at $262.63 throughout the day. The trading session low price was $257.60 and day high was $262.99 on Friday, June 26. After the session, the Healthcare sector daily volume shifted to 2.36 million while its average volume is 1.91M. In other hand, the BIIB market cap reached to $40.54B. While, its current target price is $258.66 according to WSJ.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -4.55% and down -13.92% for month. Its quarterly performance was -12.84% below, while its half year performance is down -14.29%. BIIB yearly performance stood at positive 7.88% and fall -12.83% for year-to-date. Current recommendation for Biogen Inc. is 2.80.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. BIIB EPS (TTM) for 12-month is 32.40. EPS for this year is 44.80%, while for the next year its value is 31.78. Its EPS Q/Q reached 13.00%. It has an EPS of 20.50% up for past five years and for the next five years will be down -1.59%.
Let’s take a look on the analyst recommendations on BIIB for the current month and previous month. For the current month, 9 of 33 analysts recommend stock as Buy while 3 as Sell, 1 as overweight, 2 as underweight and 18 as Hold. As compared with the previous month ratings, 33 analysts participate in stock recommendation. Out of 33, 3 rated it sell, 10 rated it as Buy and 16 as Hold Ratings. On the other hand, target price ranges from $228.00-$392.00. Average target price for BIIB was reached at $304.11.
Blackrock Inc., Primecap Management Company and Vanguard Group, Inc. (The) are the top three holders in Biogen Inc. (BIIB) stock. On Mar 30, 2020, Blackrock Inc. has 16.04 million shares which valued 5.08 billion. On Mar 30, 2020, Primecap Management Company owned 15.97 million shares which valued at 5.05 billion. On Mar 30, 2020, Vanguard Group, Inc. (The) has a total of 14.24 million shares which valued at 4.5 billion. In the end, Vanguard Group, Inc. (The) have 8.73% shares outstanding of Biogen Inc. (BIIB) on Mar 30, 2020. The insider ownership moved to 0.10% and institutional holding shifted to 91.50%.
The company posted an EPS (TTM) of 32.40. According to the most recent quarter report on (Jun 2020), 26 analysts estimated an average EPS of 8.08, while 9.15 EPS posted a year ago period. Analyst Estimated EPS for BIIB published in the report was 6.79-9.76 during the same period. Comparing with last year, the average estimated EPS was 9.15 which is higher than 9.14 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for BIIB fall -10.83% for period of 200 days. SMA for 50 days was -13.89% which is showing red signal, while SMA-20 was -9.32%. The moving average value for Biogen Inc. (BIIB) is 302.17 and 294.71 for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in BIIB stock. On Mar 11, SHERWIN STEPHEN A, Director, sold 2,434 trading shares at the cost of $295.22, which valued at 0.72 million. On Dec 02, Posner Brian S, Director, sold 1,055 shares at the cost of $292.35, with total shares of 6,995.